Monthly KwikPen OK'd
The FDA approved a monthly KwikPen option for tirzepatide (Zepbound) in chronic weight management, expanding dosing formats beyond weekly injections. (ajmc.com) The approval notes available strengths of 2.5, 5, 7.5, 10, 12.5 and 15 mg and cites maintenance dosing at 5, 10 or 15 mg once weekly for weight reduction and long‑term management. (ajmc.com)
The Food and Drug Administration has cleared a four-dose Zepbound KwikPen, letting patients get a month of tirzepatide in one pen instead of separate weekly devices. (accessdata.fda.gov) The approval letter says the new Zepbound KwikPen adds six presentations, each containing four once-weekly doses of tirzepatide. The listed strengths are 2.5, 5, 7.5, 10, 12.5 and 15 milligrams. (accessdata.fda.gov; pi.lilly.com) Tirzepatide is a prescription injection used with a reduced-calorie diet and increased physical activity for adults with obesity, or adults who are overweight with at least one weight-related condition. The Food and Drug Administration first approved Zepbound for chronic weight management in November 2023. (fda.gov) The drug still works on a once-weekly schedule. Lilly’s prescribing information says the maintenance doses for weight reduction and long-term management remain 5, 10 or 15 milligrams injected under the skin once a week, with a maximum recommended dose of 15 milligrams once weekly. (pi.lilly.com) In plain terms, the change is about the container, not a new monthly dosing regimen. The new pen holds four fixed weekly doses for a single patient, according to the Food and Drug Administration approval letter. (accessdata.fda.gov) That puts Zepbound in a format Lilly has already used outside the United States and that insulin users know well: a multi-dose pen that is dialed and used repeatedly until empty. The company’s United States patient site continues to describe Zepbound as a once-weekly injection. (zepbound.lilly.com) The label also says Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, with recommended maintenance doses of 10 or 15 milligrams once weekly for that use. The KwikPen approval updates the presentation options across the product line rather than changing those dosing recommendations. (pi.lilly.com; accessdata.fda.gov) Lilly has already started tying the new pen to cash-pay distribution. In March 2026, the company said self-pay access to Zepbound KwikPen would be available through LillyDirect and major pharmacies, with pricing starting at $299 a month for the 2.5 milligram dose. (medicalupdateonline.com) For patients, the practical shift is fewer devices to handle each month, but the treatment calendar stays the same: one tirzepatide shot every week. (pi.lilly.com; accessdata.fda.gov)
